The Pluses and Minuses of Innovation
Applied Clinical Trials
Survey delves deep into what constitutes true game-changing innovation in clinical development.
There is hype. And there is innovation. There are expectations and reality. While the chart below is from our latest survey conducted with SCORR Marketing on innovation, this question itself doesn’t use the “i” word. Something that has the “potential to change the future of clinical trials” should be considered an innovation, but of the five choices we gave, which is a true innovation? And does it matter if it indeed changes the future?
The survey delved much deeper into what respondents think about innovation, what types of innovation is or is not being implemented, and how innovation is viewed by stakeholders. These results can be download for free here.
Other items of note from the survey include the majority of respondents feel that CROs are most accepting of innovative processes, while clinical sites are not; an equal number of companies have or don’t have an innovations department or infrastructure (43.4%); and the most often cited reason for hindering adoption of technological advances is cost.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
